INHIBITION OF PACLITAXEL AGAINST NEUROGLIOMA CELLS U251 GROWTH AND ITS MECHANISM

Afr J Tradit Complement Altern Med. 2016 Nov 23;14(1):174-178. doi: 10.21010/ajtcam.v14i1.19. eCollection 2017.

Abstract

Background: Glioma is the most common primary tumor of the central nervous system, and accounted for about 70% of primary tumors.

Materials and methods: In the study, antitumour activity and mechanism of paclitaxel was investigated. Different concentrations of paclitaxel (200, 300, 400 μmol/L) was treated in neuroglioma cellsU251.

Results: Paclitaxel significantly inhibited neuroglioma cells growth, and promoted its apoptosis. Paclitaxel can block tumour cells in the G2/M phase. In addition, apoptosis-related genes caspase-3 and bax expressions were increased after paclitaxel treatment.

Conclusion: Our work indicated that paclitaxel displayed strong anti-tumour activity.

Keywords: antitumour; apoptosis; cell cycle; paclitaxel.

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Apoptosis / drug effects
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / genetics
  • Brain Neoplasms / metabolism
  • Brain Neoplasms / physiopathology*
  • Caspase 3 / genetics
  • Caspase 3 / metabolism
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Dose-Response Relationship, Drug
  • Glioma / drug therapy
  • Glioma / genetics
  • Glioma / metabolism
  • Glioma / physiopathology*
  • Humans
  • Paclitaxel / pharmacology*
  • bcl-2-Associated X Protein / genetics
  • bcl-2-Associated X Protein / metabolism

Substances

  • Antineoplastic Agents, Phytogenic
  • bcl-2-Associated X Protein
  • Caspase 3
  • Paclitaxel